StonvexLoading…
StonvexStonvexStonvexCore line items from AMTM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-10-03 | Annual 2024 2024-09-27 | Annual 2023 2023-09-29 | Annual 2022 2022-09-30 |
|---|---|---|---|---|
Revenue | $14.39B | $8.39B | $7.87B | $7.68B |
Operating Income | $480.00M | $291.00M | $57.00M | $121.00M |
Net Income | $66.00M | $-82.00M | $-314.00M | $-84.00M |
EPS (Diluted) | $0.27 | $-0.90 | $-3.49 | $-0.93 |
Total Assets | $11.46B | $11.97B | $6.41B | Not available |
Total Liabilities | $6.84B | $7.42B | $6.00B | Not available |
Cash & Equivalents | $437.00M | $452.00M | $305.00M | $366.00M |
Free Cash Flow OCF − CapEx | $516.00M | $36.00M | $55.00M | $108.00M |
Shares Outstanding | 243.46M | 243.30M | 0 | 90.00M |